Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Three Stocks Turn $10,000 To $25,265 In Just 3 Months
07:30am, Friday, 31'st Mar 2023
Investors enjoyed a small S&P 500 rally in March. But there were much more lucrative places to put money in the month.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
04:34pm, Thursday, 30'th Mar 2023 Zacks Investment Research
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
01:42pm, Thursday, 30'th Mar 2023
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
11:20am, Saturday, 25'th Mar 2023 The Motley Fool
These companies strive to bring down the cost of developing new therapies.
Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses
03:16pm, Friday, 24'th Mar 2023 Zacks Investment Research
Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.
Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses
01:00pm, Friday, 24'th Mar 2023
Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.
Catalent (CTLT) Inks Deal for New & Effective Drug Delivery
03:13pm, Monday, 20'th Mar 2023 Zacks Investment Research
Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.
Catalent (CTLT) Inks Deal for New & Effective Drug Delivery
12:14pm, Monday, 20'th Mar 2023
Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.
Catalent: Ready For Growth Despite A Tough Year, Falling Revenues And A Lawsuit
09:28am, Monday, 20'th Mar 2023
Catalent's COVID-19 related revenues have fallen, but cushioned by growth in other areas and they continue to expand their activities. A lawsuit over accusations of misleading investors is ongoing tha
Stock market volatility this week has triggered a new sell signal
10:12pm, Thursday, 16'th Mar 2023 MarketWatch
Stay cautious until new highs outnumber new lows on the NYSE.
Zoetis (ZTS) Down 6.5% Since Last Earnings Report: Can It Rebound?
03:30pm, Thursday, 16'th Mar 2023 Zacks Investment Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines
03:19pm, Thursday, 16'th Mar 2023 Zacks Investment Research
Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.
Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines
01:01pm, Thursday, 16'th Mar 2023
Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.
The stock market is telling you loud and clear: Now is not the time to fight the Fed or stand up to the bears.
02:10pm, Saturday, 11'th Mar 2023 MarketWatch
The S&P 500 faces strong resistance up to 4200, writes Lawrence McMillan.
What's Next For Catalent Stock After A 50% Rise This Year?
09:00am, Friday, 10'th Mar 2023
After a 54% rise year-to-date, at the current levels, Catalent stock (NYSE: CTLT), a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, has little room f
